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Abstract
Background: Epidermal Growth Factor Receptor (EGFR) mutations, especially in-frame deletions in exon 19 (ΔLRE)
and a point mutation in exon 21 (L858R) predict gefitinib sensitivity in patients with non-small cell lung cancer.
Several methods are currently described for their detection but the gold standard for tissue samples remains direct
DNA sequencing, which requires samples containing at least 50% of tumor cells.
Methods: We designed a pyrosequencing assay based on nested PCR for the characterization of theses mutations
on formalin-fixed and paraffin-embedded tumor tissue.
Results: This method is highly specific and permits precise characterization of all the exon 19 deletions. Its
sensitivity is higher than that of “BigDye terminator” sequencing and enabled detection of 3 additional mutations
in the 58 NSCLC tested. The concordance between the two methods was very good (97.4%). In the prospective
analysis of 213 samples, 7 (3.3%) samples were not analyzed and EGFR mutations were detected in 18 (8.7%)
patients. However, we observed a deficit of mutation detection when the samples were very poor in tumor cells.
Conclusions: pyrosequencing is then a highly accurate method for detecting ΔLRE and L858R EGFR mutations in
patients with NSCLC when the samples contain at least 20% of tumor cells.
Introduction
Detection of mutations of the epidermal growth factor
receptor (EGFR) gene is critical for predicting the
response to therapy with tyrosine kinase inhibitors
(TKIs, e.g.: gefitinib and erlotinib) in patients with non-
small-cell lung cancer (NSCLC) [1]. Practically all muta-
tions are on exons 18 through 21 where they affect the
ATP-binding cleft of EGFR [2]. In vitro studies have
shown that EGFR mutants have constitutive TK activity
and, therefore, a greater sensitivity to anti-EGFR inhibi-
tion. Two classes of mutation account for approximately
90% of EGFR mutations reported to date in lung adeno-
carcinoma [3]. The class I mutations are in-frame dele-
tions in exon 19, which almost always include amino-
acid residues leucine 747 to glutamic acid 749 (ΔLRE).
The second mutation is a single-point mutation in exon
21, which substitutes an arginine for a leucine at codon
858 (L858R).
Thus far, the direct DNA sequencing method is the
most common and conventional method used for the
detection and identification of mutations in tumor cells.
However, its sensitivity is suboptimal for clinical tumor
samples. Mutant DNA needs to comprise ≥25% of the
total DNA to be easily detected [4]. All new techniques
claim to be more sensitive with the ability to detect
mutations in samples containing ≤10% mutant alleles.
Pyrosequencing is a non-electrophoretic real time
sequencing technology with luminometric detection [5].
Not only can it detect mutations but it also permits a
mutation to be characterized and to quantify the per-
centage of mutated alleles in a sample. We have pre-
viously shown that it is a robust method to characterize
the KRAS codon 12 and 13 mutations in paraffin-
embedded samples in daily practice [6].
Here we also show that pyrosequencing is a simple
and sensitive method to detect the two most common
mutations of the EGFR TK domain, and demonstrate its
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tumor samples, in a large prospective series.
Materials and methods
Cell lines
The human lung cancer cell lines NCI-H1650 and NCI-
H1975 were obtained from the American Type Culture
Collection (ATCC). Both cell lines were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum
at 37°C in air containing 5% CO2. Peripheral Blood
Lymphocytes (PBL) used as negative control were
obtained from healthy volunteers.
Clinical samples
Between 1
st January and 30 June 2010, 213 tumor sam-
ples were collected from consecutive patients with an
advanced lung adenocarcinoma, DNA extracted and
their EGFR mutation status determined for selection for
anti EGFR treatments by clinicians. All analyses were
conducted with full respect of patients’ rights to confi-
dentiality and according to procedures approved by the
local authorities responsible for ethics in research. All
samples were histologically analyzed by an experienced
thoracic pathologist and classified according to the
WHO classification of lung cancer. For each sample, the
percent of tumor cells was determined.
DNA extraction
The DNAeasy kit (Qiagen) was used according to the
manufacturer’si n s t r u c t i o n st oe x t r a c tg e n o m i cD N A
from cells and from tumor tissues. A prolonged (48H)
proteinase K digestion was used for paraffin-embedded
tissues [6].
PCR amplification of exons 19 and 21 of the EGFR gene
PCR and sequencing primers were designed using the
PSQ assay design (Biotage) and are described in table 1.
100 ng of tumor DNA was amplified using a nested
PCR to amplify almost all samples independent of the
type of tissue fixative or of the fixative conditions.
The first PCR product was amplified at 58°C for 20
(exon 19) or 10 (exon 21) cycles. The second PCR pro-
cedure was carried out in a total volume of 50 μlc o n -
taining 2 μl of the first PCR, 20 pmol of each primer,
1.5 mmol/l MgCl2 and 1.25 U of FastStart Taq DNA
polymerase (Roche). PCR conditions consisted of initial
denaturing at 95°C for 15 min, 45 cycles at 95°C for 20
s, 62°C (exon 19) or 61°C (exon 21) for 20 s, 72°C for
20 s and a final extension at 72°C for 10 min. The PCR
products (10 μl) were analyzed by electrophoresis in a
3% agarose gel to confirm the successful amplification
of the 180-bp or the 195-bp PCR product.
Pyrosequencing analysis
40 μl of PCR product were bound to streptavidin
Sepharose HP (GE Healthcare), purified, washed, dena-
t u r e du s i n ga0 . 2m o l / lN a O Hs o l u t i o n ,a n dw a s h e d
again. Then 0.3 μmol/l pyrosequencing primer was
annealed to the purified single-stranded PCR product
and the pyrosequencing was performed on a PyroMark
ID system (Qiagen) following the manufacturer’s
instructions. The nucleotide dispensation order was
GTATCAGACATGAC for analysis of exon 19 and
CTGCGTGTCA for analysis of exon 21.
Results
Pyrosequencing assay of exon 19 deletions
In order to test the pyrosequencing method for the ana-
lysis of exon 19 deletions, we used DNA from the NCI-
H1650 cell line as positive control and DNA extracted
from human peripheral blood lymphocytes (PBL) as
wild-type control. We choose a particular pyrosequen-
cing program with the oligonucleotide dispensation
order (GTATCAGACATGAC) because it permits to
distinguish wild type and mutated alleles (table 2) gener-
ating for each sample a specific pyrogram (Figure 1A
and 1B and Figure 2). These pyrograms correspond to a
mix of wild type and mutated alleles. We quantitatively
evaluated the exon 19 deletion (c.2235-2249del; p.
Glu746-Ala750del) by determining the ratio between the
peak areas of the two adenines dispensed in positions 6
(A6)a n d8( A 8). We tested the reproducibility of the
Table 1 Sequences of primers used for pyrosequencing analysis
Exon 19 Exon 21
primer sequence T° of
hybridation
primer sequence T° of
hybridation
First 5’-GCAATATCAGCCTTAGGTGCGGCTC-3’ 58°C 5’-CTAACGTTCGCCAGCCATAAGTCC-3’ 58°C
PCR 5’-CATAGAAAGTGAACATTTAGGATGTG-3’ 5’-
GCTGCGAGCTCACCCAGAATGTCTGG-3’
second 5’-CATGTGGCACCATCTCACAAT-3’ 62°C 5’-GAATTCGGATGCAGAGCTTCTT-3’ 61°C
PCR 5’-Biotin-CCCACA CAGCAA
AGCAGAAACT-3’
5’-Biotin-CTTTCTCTTCCGCACCCA
primer for sequence
reaction
5’-TAAAATTCCCGTCGC-3’ 5’-CATGTCAAGACTACAGATT-3’
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independent runs. We found an A6/A8 ratio of 1.06 ±
0.04 for the wild type sample and 4.59 ± 0.33 for the
sample with the deletion. The relative standard deviation
(RSD) was respectively 3.9% and 7.2%. Thus, a sample
could be considered as mutated if A6/A8 was superior to
1.2 (corresponding to [the mean + 3 standard devia-
tions] of the wild type sample). To demonstrate the
assay sensitivity, we also quantified the A6/A8 ratio in
v a r i o u sm i x t u r e s( 1 0 / 0 ,9 / 1 ,8 / 2 ,7 / 3 ,6 / 4 ,5 / 5 ,4 / 6 ,3 / 7 ,
2/8, 1/9 and 0/10) of DNA from the NCI-H1650 cell
line with DNA from peripheral blood lymphocytes (Fig-
ure 1C). Each mixture was analyzed 5 times in the same
r u na n dw ef o u n da nA 6/A8 ratio varying from 5.27 ±
0.38 (mixture 10/0) to 1.11 ± 0.05 (mixture 0/10). We
determined that all the mixtures containing at least 20%
of NCI-H1650 DNA have an A6/A8 ratio superior to 1.2
and could be considered as mutated.
Moreover, the pyrosequencing program that analyzed
the deletions in exon 19 was designed to detect almost
all types of deletion (figure 2). In comparison with the
graph obtained with the wild type sample, the diminu-
tion of several peaks (marked *) and the emergence of
new ones (marked ◊) were considered as specific of a
deletion (table 2).
Pyrosequencing assay of L858R exon 21 point mutation
L858R-specific pyrosequencing was performed using the
NCI-H1975 cell line and a percentage of T > G muta-
tion was determined (Figure 3). The result obtained
with 20 consecutive runs, was 46.2 ± 3% with good
reproducibility (RSD = 6.4%). We also determined the
Table 2 Sequencing of wild type and mutated alleles with a particular program of pyrosquencing
nucleotide dispensation during pyrosequencing G T A T C A G A C A T G A C
WT T A T C AA GG AA TT AA
allelic c.2235-2249del TATCA A AA C A T C
sequence of c.2236-2250del TATC A A G AC AT C
c.2237-2251del TATC A A G G CA T C
c.2240-2257del T A T C AA GG AA T C
Bold letters correspond to the nucleotides identical in wild type and mutated alleles; italic letters correspond to the nucleotides specific of mutated alleles.
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Figure 1 Analysis of exon 19 deletions by pyrosequencing. The analysis was performed with PBL DNA (A) as wild-type control and with
NCI-H1650 DNA (B) as deletion control. The deletion was quantified by determining the ratio between the A8 and A6 peak areas. (C) The
sensitivity was characterized by measuring A8/A6 ratio in different mixtures of NCI-H1650 DNA and PBL DNA.
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ious mixtures (10/0, 9/1, 8/2, 7/3, 6/4, 5/5, 4/6, 3/7, 2/8,
1/9 and 0/10) of DNA from the NCI-H1975 cell line
and DNA from peripheral blood lymphocytes (Figure
3C). We detected the percentage of T > G mutation
with a linear variation (R
2 = 0.99) from 39.6 ± 0.6%
(mixture 10/0) to 7.7 ± 1.7% (mixture 4/6) and a relative
standard deviation varying from 1.4 to 15.9%. We also
determined a% of mutation for the mixtures 3/7 and 2/8
with a CV largely higher then 20%.
EGFR mutation in tumor samples
We compared the results obtained previously by con-
ventional BigDye Terminator sequencing [7] using the
method described by Pao et al [8] and those obtained by
pyrosequencing 58 of these tumor samples (Table 3). All
mutated samples were confirmed twice, starting from
independent polymerase chain reactions. We observed a
very high concordance between the two methods (56/58
(96.6%) for exon 19 and 57/58 (98.3%) for exon 21 ana-
lysis). For 3 samples (3/58; 5%), results were discordant
and mutations were detected only by pyrosequencing
and not by Big Dye terminator sequencing, reflecting
the lower sensitivity of the classical sequencing method.
Indeed, the two samples with an exon 19 deletion have
an A6/A8 ratio of 1.7 and 1.8 which correspond to less
of 25% of mutated alleles (figure 1C). For the sample
with a L858R mutation detected only by pyrosequen-
cing, we found that only 22.5% of the DNA was
mutated.
We then determined the EGFR status of 213 patients
with advanced or metastatic lung adenocarcinomas for
c.2235_2249del; p.Glu746_Ala750del
c.2236_2250del; p.Glu746_Ala750del
c.2237_2251del; p.Glu746_Thr751delinsAla
c.2240_2257del; p.Leu747_Pro753delinsSer
Wild type
** * *
** *
*
*
*
*
*
*
¸¸ ¸
¸¸ ¸
¸¸ ¸
¸
Figure 2 Comparison of different pyrograms observed for exon 19 analyses in different tumor tissues. The exon 19 status were
described as wild type or deleted (*: peak diminished in the deleted samples; ◊: peak increased in the deleted samples).
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(3.3%) samples were inconclusive due to poor DNA
quality with no DNA amplification. Of the 206 remain-
ing samples, 18 EGFR mutations were detected (8 of
exon 19 and 10 of exon 21) (18/206; 8.7%). Among
these 206 specimens, 36 had less than 20% of tumor
cells and only one with a mutation was detected (1/36;
2.8%). For the 170 specimens containing more than 20%
of tumor cells, 17 with mutations were found (17/170;
10%).
Discussion
Pyrosequencing is sensitive and enables accurate detec-
tion of mutations. A previous study has described the
capacity of this method to detect small insertions [9]
but this study is the first to demonstrate the application
of pyrosequencing to exon 19 deletions. Analysis of
exon 21 by pyrosequencing had been succinctly
described by Takano et al. [10,11], but without any data
about the specificity, the repeatability or the sensitivity.
We first investigated the characteristics of EGFR
mutations in the lung cancer cell lines NCI-H1650 and
NCI-H1975 and used them as positive controls for the
deletion in exon19 and the point mutation in exon 21
respectively. Moreover we used the DNA of these cells
mixed with DNA isolated from blood samples from
healthy volunteers to evaluate the basic properties of
our novel method. We didn’t observe strict linearity
because the two cell lines (NCI-H1650 and NCI-H1975)
have respectively 4 and 2.8 EGFR gene copies [12] but
we found good sensitivity.
In routine daily practice fixed paraffin-embedded spe-
cimens, most often of small size, are the only samples
available for both diagnosis and molecular analyses. The
DNA is frequently fragmented, which could hamper
PCR amplification. However, the PCR conditions
described in this study allowed analysis of 96.7% of the
paraffin-embedded tissues whatever the type of fixative
used or the duration of the fixation. When the samples
could be amplified and analyzed, results were concor-
dant (97.4%) with those obtained by conventional Big-
Dye terminator sequencing. The difference in sensitivity
between the two methods is illustrated by the 3 samples
characterized as mutated only by pyrosequencing. The
frequency of deletions in exon 19 and mutations in
exon 21 among the NSCLC patients was almost
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Figure 3 Analysis of c.2573T > G; p.Leu858Arg exon 21 mutation by pyrosequencing. Examples of pyrosequencing profiles obtained with
PBL (A) and NCI-H1975 (B) DNA.* represented the T > G mutation. (C) Sensitivity curve established with different mixtures of NCI-H1975 and PBL
DNA.
Table 3 Comparison of EGFR status (wild type (WT) or mutant (M)) of exon 19 and exon 21 determined by big dye
sequencing or by pyrosequencing on 58 NSCLC tissues
Exon 19 big dye sequencing Exon 21 big dye sequencing
WT M WT M
pyrosequencing WT 47 / pyrosequencing WT 53 /
M2 9 M1 4
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Caucasian populations [13]. These samples were also
analyzed for KRAS mutations because (i) EGFR and
KRAS mutations are mutually exclusive in NSCLC and
(ii) emerging data suggest that KRAS mutations are
negative predictors of benef i tf r o mb o t ha d j u v a n tc h e -
motherapy and anti-EGFR-directed therapies [12,14,15].
We found 26.7% of the samples with a KRAS mutation
(data not shown). This is also in accordance with the lit-
erature [14] and validated our cohort as being well
representative. We found 8 exon 19 deletions and 10
exon 21 mutations. These results were in accordance
with those described by Tanaka et al. [16]. They noticed
that exon 19 deletions were significantly associated with
a male gender. In our cohort, 15 of the 18 patients with
EGFR mutations were female.
We observed a deficit in mutation detection when the
samples were very poor in tumor cells whereas the
others could be accurately analyzed. As only bronchial
or trans-thoracic fine needle biopsies are usually avail-
able in the medical setting of patients with advanced
stage NSCLC (around 90% of the samples analyzed here,
with only 10% being surgical specimens), these results
demonstrate the need for a pathologist’s expertise to
qualify the samples and perform microdissection if sam-
ples contain less than 20% of tumor cells. Indeed,
Masago et al. [17] have demonstrated that results could
be obtained from biopsy specimens only if the quantity
of the specimen is sufficient to make a pathological
diagnosis and if cancer cells were carefully selected.
However, microdissection is very time-consuming and it
is not always possible. Alternatively, methods such as
peptide nucleic acid-locked nucleic acid PCR clamp
[18,19] or real-time PCR based on scorpion primers
coupled with the Amplified Refractory Mutation System
(ARMS) [20] have a sensitivity around 1% of cancer
cells. However, they could be difficult to use in routine
clinical assay because they require special equipments
and expensive reagents.
Conclusions
The present pyrosequencing method is sufficiently sensi-
tive and specific to enable the detection of the two major
TKI-sensitive mutations in a large majority of the DNA
extracted from paraffin-embedded clinical samples.
Acknowledgements and funding
Excellent technical support was provided by Emilie Bonin, Monique Delon,
Valérie Konik-Mathevet, Maryse Samuel and Odile Vermeulen. We also
acknowledge the Department of Cytology and Pathology for tumor sample
preparations. We thank Dr Alison Foote for correcting our English usage.
This project was supported by the clinical research direction of the
Grenoble’s hospital, INCa (the French National Cancer Institute) and the
French ministry of health initiated the ERMETIC project.
Author details
1UM Biochimie des Cancers et Biothérapies, CHU Grenoble, Institut de
Biologie et Pathologie, parvis Belledonne, 38 043 Grenoble, France.
2Centre
de recherche INSERM/UJF U823, Institut Albert Bonniot, Rond-point de la
Chantourne, 38 709 La Tronche cedex 9, France.
3Département d’Anatomie
et Cytologie Pathologiques, CHU Grenoble, Institut de Biologie et Pathologie,
parvis Belledonne, 38 043 Grenoble, France.
Authors’ contributions
SD carried out the molecular analysis, MJR participated in the design of the
study and drafted the manuscript, SL carried out immunohistochemestry
analysis, FdeF designed the study, carried out the molecular analysis and
drafted the manuscript. All authors reviewed the draft manuscript, read and
approved the final version for submission.
Competing interests
The authors declare that they have no competing interests.
Received: 7 March 2011 Accepted: 16 May 2011 Published: 16 May 2011
References
1. Govindan R: INTERESTing biomarker to select IDEAL patients for
epidermal growth factor receptor tyrosine kinase inhibitors: yes, for
EGFR mutation analysis, others, I PASS. J Clin Oncol 28:713-715.
2. Gazdar AF: Personalized medicine and inhibition of EGFR signaling in
lung cancer. N Engl J Med 2009, 361:1018-1020.
3. Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell
lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Oncogene 2009, 28(Suppl 1):S24-31.
4. Pao W, Ladanyi M: Epidermal growth factor receptor mutation testing in
lung cancer: searching for the ideal method. Clin Cancer Res 2007,
13:4954-4955.
5. Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time
pyrophosphate. Science 1998, 281:363-365.
6. Dufort S, Richard MJ, de Fraipont F: Pyrosequencing method to detect
KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.
Anal Biochem 2009, 391:166-168.
7. Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V,
Mauguen A, Barbu V, Coulet F, Pretet JL, Bieche I, Blons H, Boyer JC,
Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-
Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G,
Hainaut P, Michiels S, Cadranel J: Cross-Validation Study for Epidermal
Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded
Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons
Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR
Mutation Status for the Administration of EGFR-TKIs in Non-Small Lung
Carcinoma [ERMETIC] Project-Part 1). J Thorac Oncol 2011.
8. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R,
Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF
receptor gene mutations are common in lung cancers from “never
smokers” and are associated with sensitivity of tumors to gefitinib and
erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
9. Guo DC, Qi Y, He R, Gupta P, Milewicz DM: High throughput detection of
small genomic insertions or deletions by Pyrosequencing. Biotechnol Lett
2003, 25:1703-1707.
10. Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H,
Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M,
Table 4 Prospective evaluation of the EGFR status of
exons 19 and 21
% of tumoral tumoral samples (n =
206)
EGFR mutations (n =
18)
cells number % exon 19 exon 21 %
<20% 36 17.5 0 1 2.8
from 20 to 50% 98 47.6 3 6 9.2
>50% 72 35 5 3 11.1
Samples may contain at least 20% of tumor cells to allow a correct detection
of mutations
Dufort et al. Journal of Experimental & Clinical Cancer Research 2011, 30:57
http://www.jeccr.com/content/30/1/57
Page 6 of 7Kusumoto M, Yamamoto S, Yoshida T, Tamura T: Prospective study of the
accuracy of EGFR mutational analysis by high-resolution melting analysis
in small samples obtained from patients with non-small cell lung
cancer. Clin Cancer Res 2008, 14:4751-4757.
11. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S,
Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T,
Yoshida T, Tamura T: Epidermal growth factor receptor gene mutations
and increased copy numbers predict gefitinib sensitivity in patients with
recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
12. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H,
Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD,
Gazdar AF: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer
cell lines. PLoS One 2009, 4:e4576.
13. Pircher A, Ploner F, Popper H, Hilbe W: Rationale of a relaunch of gefitinib
in Caucasian non-small cell lung cancer patients. Lung Cancer 69:265-271.
14. Riely GJ, Marks J, Pao W: KRAS mutations in non-small cell lung cancer.
Proc Am Thorac Soc 2009, 6:201-205.
15. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA: Personalized Medicine in
Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting
Patients for Epidermal Growth Factor Receptor-Targeted Therapy? J Clin
Oncol 2011.
16. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A,
Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G,
Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K: Frequency of
and variables associated with the EGFR mutation and its subtypes. Int J
Cancer 126:651-655.
17. Masago K, Fujita S, Mio T, Ichikawa M, Sakuma K, Kim YH, Hatachi Y,
Fukuhara A, Kamiyama K, Sonobe M, Miyahara R, Date H, Mishima M:
Accuracy of epidermal growth factor receptor gene mutation analysis
by direct sequencing method based on small biopsy specimens from
patients with non-small cell lung cancer: analysis of results in 19
patients. Int J Clin Oncol 2008, 13:442-446.
18. Nagai Y, Miyazawa H, Huqun , Tanaka T, Udagawa K, Kato M, Fukuyama S,
Yokote A, Kobayashi K, Kanazawa M, Hagiwara K: Genetic heterogeneity of
the epidermal growth factor receptor in non-small cell lung cancer cell
lines revealed by a rapid and sensitive detection system, the peptide
nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005,
65:7276-7282.
19. Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, Huqun ,
Udagawa K, Murayama Y, Nagata M, Shimizu Y, Ikebuchi K, Kanazawa M,
Kobayashi K, Hagiwara K: Reliability of the peptide nucleic acid-locked
nucleic acid polymerase chain reaction clamp-based test for epidermal
growth factor receptor mutations integrated into the clinical practice for
non-small cell lung cancers. Cancer Sci 2007, 98:246-252.
20. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B,
Nishio K: Detection of epidermal growth factor receptor mutations in
serum as a predictor of the response to gefitinib in patients with non-
small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.
doi:10.1186/1756-9966-30-57
Cite this article as: Dufort et al.: Pyrosequencing, a method approved to
detect the two major EGFR mutations for anti EGFR therapy in NSCLC.
Journal of Experimental & Clinical Cancer Research 2011 30:57.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dufort et al. Journal of Experimental & Clinical Cancer Research 2011, 30:57
http://www.jeccr.com/content/30/1/57
Page 7 of 7